Clinical Overview of Parkinson's Disease: The Progressive Impact on Patients and Their Care Partners
This webinar was recorded on October 25, 2022
Sponsored by Abbvie
This webinar is intended for US Formulary decision-makers only.
In a healthy brain, release of dopamine from neurons activates dopamine receptors that are responsible for mediating motor activity. The hallmark histopathologic features of PD are the loss of dopamineproducing neurons and the presence of Lewy bodies in the remaining neurons found in the substantia nigra. The loss of dopaminergic terminals in the striatum is crucial for onset of motor symptoms) such as tremor, rigidity, and bradykinesia.
Non-motor symptoms (NMS) such as anxiety, depression, gastrointestinal problems, loss of smell, insomnia, and pain often occur prior to a diagnosis of PD and continue throughout the course of disease. Dysregulation of a number of dopaminergic and non-dopaminergic pathways are likely contributing to NMS including noradrenergic, glutamatergic, serotonergic, as well as other pathways.
The objective of this webinar is to talk about the complexities of Parkinson’s Disease and to provide an overview of the treatment options that are currently available.
- Review the Movement Disorder Society clinical criteria for diagnosis of Parkinson’s Disease as well as the impact of motor and non-motor symptoms.
- Understand the clinical and economic burden of Advancing Parkinson’s Disease to the patient and caregivers.
- Discuss the current treatment options available to patients living with Parkinson’s Disease.
- Review suggested criteria when a patient is considering a Device Aided Treatment option.
Sandeep Thakkar, DO
CEO/Director at Movement Disorder Parkinson’s Disease Specialists
Movement Disorder Sub-Specialist/Neurologist - Hoag Memorial Hospital Presbyterian
Newport Beach, CA
This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not AMCP.
AbbVie US Medical Affairs